Invasion characteristics of oral tongue cancer

Abstract

Background This study explored the blood transfusion patterns, SCD complications, utilization of iron chelation therapies (ICT), healthcare resource use, and costs in pediatric, transitioning (18 years old) and adult patients with SCD. Procedure Data from Florida (1998–2009), New Jersey (1996–2009), Missouri (1997–2010), Kansas (2001–2009), and Iowa (1998–2010) state Medicaid were used. Patients with ≥2 SCD diagnoses and ≥1 transfusion event were included. Rates of transfusion events, SCD complications, and proportion of eligible patients receiving ICT were calculated. ICT eligibility was defined as receiving ≥10 transfusions over lifetime. SCD complications included pain, pulmonary event, infection event, renal, cardiovascular, stroke, leg ulcers, and avascular necrosis. Regressions were used to assess risk factors for transfusion and identify the main drivers of costs. Results The sample included 3,208 patients. The transfusion rate increased from 1‐year‐old to a peak at 16 years old, then dropped until age 26 and remained stable thereafter. In contrast the frequency of diagnoses for SCD complications increased markedly after age 16. Post‐transition patients (≥18 years old) were significantly associated with fewer transfusions (odds ratio: 0.80, P = 0.002). Among eligible patients for ICT, there was no statistically significant difference in total cost between the ICT and no ICT groups (adjusted cost difference, $136, P = 0.114). Conclusions Patients transitioning to adult care received less transfusions and hydroxyurea, less ICT when eligible for chelation therapy, had higher healthcare costs and suffered from more frequent SCD related complications than pediatric patients. These findings highlight the changes in treatment patterns corresponding to transition to adult care. Pediatr Blood Cancer 2013; 60: 828–835. © 2013 Wiley Periodicals, Inc.

Prognostic Value of Perineural Invasion in Oral Tongue Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

“…PNI has been reported to be associated with cancer outcomes in various types of cancer (8)(9)(10)(11), including HNSCC (19-21) and OTSCC (20,27,28,30,43,48,50), but the findings in OTSCC are not unanimous (25,26,31,32,44,46). Nevertheless, when synthesized using the meta-analysis methodology, these conflicting studies support that PNI is associated with locoregional recurrence and poor OS, DFS, and CSS.…”

“…The presence of PNI was associated with a higher risk of local locoregional recurrence in the non-adjusted (HR=2.46, 95%CI: 1.59-3.79, P<0.001, I 2 = 0.0%, P heterogeneity =0.661) but not in the adjusted (HR=1.93, 95%CI: 0.83-4.49, P=0.126, I 2 = 64.0%, P h e t e r o g e n e i ty =0.096) analyses (Figure 2B). The presence of PNI was reported with a worse OS (20,27,30,47,48) in the adjusted analysis (HR=1.94, 95%CI: 1.39-2.72, P<0.001, I 2 = 0.0%, P heterogeneity =0.838) but not in the nonadjusted ones (25, 30, 32) (HR=1.65, 95%CI: 0.94-2.90, P=0.079, I 2 = 65.5%, P heterogeneity =0.055) (Figure 3 and Table 2).…”

“…Table 1 presents the characteristics of the studies (20,(25)(26)(27)(28)(29)(30)(31)(32)(43)(44)(45)(46)(47)(48)(49)(50), including one RCT (43), three prospective cohort studies (44)(45)(46), and 13 retrospective studies (20,(25)(26)(27)(28)(29)(30)(31)(32)(47)(48)(49)(50). Eight studies were from Asia (20,30,32,43,44,46,47,50), one was Australia (45), three were from Europe (25,28,29), and five were from North America (26,27,31,48,49). The 17 studies included a total of ...…”

“…Supplementary Table S1 shows that the RCT (43) had a low risk of bias. Among the cohort studies, three (26,30,49) scored 7 stars, four (27,29,47,48) scored 8 stars, and two (44, 45) scored 9 stars (Supplementary Table S1). For the other studies evaluated using MINORS, one (32) scored 5 points, five (20, 25, 28, 31, 50) scored 6 points, and one (46) scored 8 points (Supplementary Table S3).…”

Overexpression of Translocation Associated Membrane Protein 2 Leading to Cancer-Associated Matrix Metalloproteinase Activation as a Putative Metastatic Factor for Human Oral Cancer

“…Since the 5-year survival rate is less than 20% in patients with OSCC with metastasis to the regional lymph nodes 31 - 34 , tumoral metastasis is a significant prognostic factor. However, there currently is no critical marker for diagnostic/therapeutic targets for patients with OSCC with metastatic lesion(s).…”